Legend Biotech Corporation (LEGN)
NASDAQ: LEGN · Real-Time Price · USD
34.34
+0.46 (1.36%)
At close: Sep 16, 2025, 4:00 PM EDT
34.50
+0.16 (0.47%)
After-hours: Sep 16, 2025, 6:22 PM EDT
Legend Biotech Stock Forecast
Stock Price Forecast
The 11 analysts that cover Legend Biotech stock have a consensus rating of "Strong Buy" and an average price target of $73.36, which forecasts a 113.63% increase in the stock price over the next year. The lowest target is $54 and the highest is $86.
Price Target: $73.36 (+113.63%)
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for Legend Biotech stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Apr '25 | May '25 | Jun '25 | Jul '25 | Aug '25 | Sep '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 5 | 5 | 5 | 4 | 4 | 4 |
| Buy | 7 | 7 | 7 | 6 | 7 | 7 |
| Hold | 1 | 1 | 1 | 1 | 1 | 1 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 13 | 13 | 13 | 11 | 12 | 12 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Cantor Fitzgerald | Cantor Fitzgerald | Buy Initiates $55 → $66 | Buy | Initiates | $55 → $66 | +92.20% | Aug 27, 2025 |
| JP Morgan | JP Morgan | Buy Maintains $77 → $78 | Buy | Maintains | $77 → $78 | +127.14% | Aug 25, 2025 |
| RBC Capital | RBC Capital | Buy Maintains $75 → $77 | Buy | Maintains | $75 → $77 | +124.23% | Aug 12, 2025 |
| Morgan Stanley | Morgan Stanley | Buy Maintains $81 → $83 | Buy | Maintains | $81 → $83 | +141.70% | Aug 12, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $75 | Strong Buy | Reiterates | $75 | +118.40% | Jul 17, 2025 |
Financial Forecast
Revenue This Year
1.07B
from 627.24M
Increased by 70.75%
Revenue Next Year
1.63B
from 1.07B
Increased by 52.47%
EPS This Year
-0.88
from -0.97
EPS Next Year
0.61
from -0.88
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 1.2B | 2.0B | |||
| Avg | 1.1B | 1.6B | |||
| Low | 970.3M | 1.4B |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 90.2% | 91.3% | |||
| Avg | 70.7% | 52.5% | |||
| Low | 54.7% | 31.4% |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | -0.28 | 1.35 | |||
| Avg | -0.88 | 0.61 | |||
| Low | -1.66 | 0.13 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | - | - | |||
| Avg | - | - | |||
| Low | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.